Wednesday, October 03, 2018 10:30:50 PM
Congrats Bio , excellent review of the research efforts over the past 30 + years !
Glad to see that you also still have confidence in murine studies !
Concerning Dr.Rudi Tanzi , please review my post # 121017 from Sept 20 ,2017 , in which I outlined some of The statements Dr.Tazi made on data presented at the 2017 AAIC held in July in London , England , and several of Dr . Tanzi’s ongoing lab studies .
It is interesting to note that Dr.Tanz’s research was suggesting that plaque formation was / is actually a defense mechanism , to protect the brain from sources of infection ( bacteria, viruses, etc ) , however he did still feel that an accumulation of plaque can lead to Alzheimers ..
Plaque formation may also occur as a response to inflammation caused by various triggers .
IMHO Anavex remains the current “ World’s Best Hope “ for solving many CNS diseases .
The next 3 to 6 months will be exciting !
Please continue your excellent analyses of evolving research , especially with our currently hidden ( or ignored ) diamond !
GLTAL !
Glad to see that you also still have confidence in murine studies !
Concerning Dr.Rudi Tanzi , please review my post # 121017 from Sept 20 ,2017 , in which I outlined some of The statements Dr.Tazi made on data presented at the 2017 AAIC held in July in London , England , and several of Dr . Tanzi’s ongoing lab studies .
It is interesting to note that Dr.Tanz’s research was suggesting that plaque formation was / is actually a defense mechanism , to protect the brain from sources of infection ( bacteria, viruses, etc ) , however he did still feel that an accumulation of plaque can lead to Alzheimers ..
Plaque formation may also occur as a response to inflammation caused by various triggers .
IMHO Anavex remains the current “ World’s Best Hope “ for solving many CNS diseases .
The next 3 to 6 months will be exciting !
Please continue your excellent analyses of evolving research , especially with our currently hidden ( or ignored ) diamond !
GLTAL !
Recent AVXL News
- Form 8-K - Current report • Edgar (US Regulatory) • 05/22/2026 12:15:26 PM
- Anavex Life Sciences Receives Expected Nasdaq Delinquency Notification • GlobeNewswire Inc. • 05/22/2026 12:00:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 05/15/2026 08:15:25 PM
- Form 3 - Initial statement of beneficial ownership of securities • Edgar (US Regulatory) • 05/14/2026 08:15:30 PM
- Form NT 10-Q - Notification of inability to timely file Form 10-Q or 10-QSB • Edgar (US Regulatory) • 05/11/2026 08:30:22 PM
- CEO Transition and Delayed SEC Filing Put Anavex (AVXL) Leadership Changes in Focus • IH Market News • 05/06/2026 02:52:36 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 05/06/2026 11:04:59 AM
- Anavex Life Sciences Board of Directors Appoints Former Senior Vice President of Clinical Development Terrie Kellmeyer, PhD, as Interim Chief Executive Officer • GlobeNewswire Inc. • 05/06/2026 11:00:00 AM
- Form 3 - Initial statement of beneficial ownership of securities • Edgar (US Regulatory) • 05/01/2026 11:18:47 PM
- Anavex Life Sciences Highlights New Scientific Findings on Shared Biology Between Autism and Alzheimer’s Disease • GlobeNewswire Inc. • 04/14/2026 11:30:00 AM
- Anavex Life Sciences to Present at the 25th Annual Needham Virtual Healthcare Conference • GlobeNewswire Inc. • 04/07/2026 11:30:00 AM
- Anavex withdraws EU approval filing for Alzheimer’s therapy • IH Market News • 03/30/2026 12:39:26 PM
- Anavex Life Sciences Provides Comprehensive Regulatory Update • GlobeNewswire Inc. • 03/30/2026 11:30:00 AM
- Form 8-K - Current report • Edgar (US Regulatory) • 03/25/2026 08:06:00 PM
- Anavex withdraws EU marketing application for Alzheimer’s therapy blarcamesine • IH Market News • 03/25/2026 02:06:58 PM
- Anavex Life Sciences Provides Update on Regulatory Review in the EU for Blarcamesine to Treat Early Alzheimer’s Disease • GlobeNewswire Inc. • 03/25/2026 11:30:00 AM
- Anavex Life Sciences Presents New Data from its AD-004 Phase IIb/III Trial at AD/PD 2026 Conference Demonstrating Consistent Correlation Between the Treatment Effect of Oral Blarcamesine and Preservation of Brain Volume in Early Alzheimer’s Disease • GlobeNewswire Inc. • 03/23/2026 11:30:00 AM
- New Scientific Findings Highlight Hypothesis of Autophagy Failure as a Precursor of Amyloid Beta and Tau Pathology in Alzheimer’s Disease • GlobeNewswire Inc. • 03/20/2026 11:30:00 AM
- Anavex Life Sciences Presents Significant Treatment Effects of Blarcamesine in New Advanced Alpha-Synuclein Model of Parkinson’s Disease at AD/PD 2026 Conference • GlobeNewswire Inc. • 03/17/2026 11:30:00 AM
- Anavex Life Sciences to Present at the Citizens Life Sciences Conference • GlobeNewswire Inc. • 03/03/2026 12:30:00 PM
- Anavex Life Sciences to Present at the 46th TD Cowen Annual Health Care Conference • GlobeNewswire Inc. • 02/25/2026 12:30:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 02/25/2026 11:07:01 AM
- Anavex Life Sciences Appoints Seasoned Healthcare Leader to Board of Directors • GlobeNewswire Inc. • 02/23/2026 12:30:00 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 02/09/2026 09:40:27 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 02/09/2026 12:31:17 PM
